Relationship between platelet count and bleeding risk in thrombocytopenic patients

被引:226
作者
Slichter, SJ [1 ]
机构
[1] Univ Washington, Sch Med, Puget Sound Blood Ctr, Seattle, WA 98104 USA
关键词
D O I
10.1016/j.tmrv.2004.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelets are lost from circulation by 2 mechanisms: senescence and random loss. Approximately 7.1 x 10(3) platelets/wL/d are postulated to be randomly used in maintaining vascular integrity. Thus, in clinically stable patients, major bleeding is unusual unless the platelet count is less than or equal to5 x 10(3)/wL. Risk factors for bleeding at higher platelet counts are disseminated intravascular coagulation with contributory clotting factor deficiencies, structural lesions with loss of vascular integrity, and refractoriness to platelet transfusions. Several large studies have documented the safety of lowering the prophylactic platelet transfusion trigger from the previously used 20 x 10(3)/muL to 10 x 10(3)/muL. A few studies have even suggested that a 5 x 10(3)/muL trigger is acceptable. Based on these results, the next step of giving just therapeutic platelet transfusions is being evaluated. In a large retrospective study, the most significant predictor of bleeding was not the patient's platelet count but a history of bleeding in the prior 5 days. These data suggest that attention should be focused on providing aggressive platelet therapy for active bleeding rather than transfusing platelets prophylactically. Therapeutic platelet transfusions have been documented to control bleeding, and mortality rates are not increased when comparing patients receiving therapeutic to that seen in patients receiving prophylactic platelet transfusions. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:153 / 167
页数:15
相关论文
共 50 条
[1]  
AURSNES I, 1974, SCAND J HAEMATOL, V13, P184
[2]   IDENTIFICATION AND CLONING OF A MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR THAT IS A LIGAND FOR THE CYTOKINE RECEPTOR MPL [J].
BARTLEY, TD ;
BOGENBERGER, J ;
HUNT, P ;
LI, YS ;
LU, HS ;
MARTIN, F ;
CHANG, MS ;
SAMAL, B ;
NICHOL, JL ;
SWIFT, S ;
JOHNSON, MJ ;
HSU, RY ;
PARKER, VP ;
SUGGS, S ;
SKRINE, JD ;
MEREWETHER, LA ;
CLOGSTON, C ;
HSU, E ;
HOKOM, MM ;
HORNKOHL, A ;
CHOI, E ;
PANGELINAN, M ;
SUN, Y ;
MAR, V ;
MCNINCH, J ;
SIMONET, L ;
JACOBSEN, F ;
XIE, C ;
SHUTTER, J ;
CHUTE, H ;
BASU, R ;
SELANDER, L ;
TROLLINGER, D ;
SIEU, L ;
PADILLA, D ;
TRAIL, G ;
ELLIOTT, G ;
IZUMI, R ;
COVEY, T ;
CROUSE, J ;
GARCIA, A ;
XU, W ;
DELCASTILLO, J ;
BIRON, J ;
COLE, S ;
HU, MCT ;
PACIFICI, R ;
PONTING, I ;
SARIS, C ;
WEN, D .
CELL, 1994, 77 (07) :1117-1124
[3]   INCIDENCE OF HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH CANCER [J].
BELT, RJ ;
LEITE, C ;
HAAS, CD ;
STEPHENS, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (24) :2571-2574
[4]   A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation [J].
Bernstein, SH ;
Nademanee, AP ;
Vose, JM ;
Tricot, G ;
Fay, JW ;
Negrin, RS ;
DiPersio, J ;
Rondon, G ;
Champlin, R ;
Barnett, MJ ;
Cornetta, K ;
Herzig, GP ;
Vaughan, W ;
Geils, G ;
Keating, J ;
Messner, H ;
Wolff, SN ;
Miller, KB ;
Linker, C ;
Cairo, M ;
Hellmann, S ;
Ashby, M ;
Stryker, S ;
Nash, RA .
BLOOD, 1998, 91 (09) :3509-3517
[5]   THE MPI RECEPTOR IS EXPRESSED IN THE MEGAKARYOCYTIC LINEAGE FROM LATE PROGENITORS TO PLATELETS [J].
DEBILI, N ;
WENDLING, F ;
COSMAN, D ;
TITEUX, M ;
FLORINDO, C ;
DUSANTERFOURT, I ;
SCHOOLEY, K ;
METHIA, N ;
CHARON, M ;
NADOR, R ;
BETTAIEB, A ;
VAINCHENKER, W .
BLOOD, 1995, 85 (02) :391-401
[6]  
DUTCHER JP, 1984, CANCER, V53, P557, DOI 10.1002/1097-0142(19840201)53:3<557::AID-CNCR2820530331>3.0.CO
[7]  
2-7
[8]   Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia [J].
Elting, LS ;
Rubenstein, EB ;
Martin, CG ;
Kurtin, D ;
Rodriguez, S ;
Laiho, E ;
Kanesan, K ;
Cantor, SB ;
Benjamin, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :1137-1146
[9]  
FANNING J, 1995, GYNECOL ONCOL, V59, P191
[10]   Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? [J].
Friedmann, AM ;
Sengul, H ;
Lehmann, H ;
Schwartz, C ;
Goodman, S .
TRANSFUSION MEDICINE REVIEWS, 2002, 16 (01) :34-45